Active Biotech AB (publ) (FRA:BTPC)

Germany flag Germany · Delayed Price · Currency is EUR
0.0041
+0.0008 (24.24%)
Last updated: Feb 23, 2026, 8:11 AM CET
Market Cap11.60M -1.5%
Revenue (ttm)n/a
Net Income-3.48M
EPS-0.00
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume4,882
Open0.0041
Previous Close0.0033
Day's Range0.0041 - 0.0041
52-Week Range0.0016 - 0.0307
Betan/a
RSI45.08
Earnings DateFeb 12, 2026

About Active Biotech AB

Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as non-infectious uveitis; Tasquinimod, an orally active small molecule immunomodulator that blocks tumor-promoting signals in the bone marrow microenvir... [Read more]

Industry Pharmaceutical Preparations
Founded 1983
Employees 5
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol BTPC
Full Company Profile

Financial Performance

Financial numbers in SEK Financial Statements

News

Active Biotech AB: Active Biotech's patent related to a pharmaceutical formulation of tasquinimod will be granted in the US

Lund, November 25, 2025, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent and Trademark Office (USPTO) has issued a notification that the company's patent application rela...

3 months ago - Finanz Nachrichten